Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyVisceral SurgeryDiseaseColon CancerFallopian Tube CarcinomaGastric CancerOvarian TumorPeritoneal Carcinomatosis, SecondarySubgroupBRCA mutationserous, borderlineserous, low-gradeICD10C16.-C16.0C18.0C18.2C18.3C18.4C18.5C18.6C18.7C18.8C19C56C57.0C78.6MeSHCarcinoma, Ovarian EpithelialColorectal NeoplasmsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal NeoplasmsSequenceChemotherapyChemo-substanceBevacizumabBinimetinibCisplatinCyclophosphamideFluorouracilMitomycinNab-paclitaxelNiraparibOlaparibPembrolizumabChemo-substanceBevacizumabBinimetinibCisplatinCyclophosphamideFluorouracilMitomycinNab-paclitaxelNiraparibOlaparibPembrolizumabChemo-substanceBevacizumabBinimetinibCisplatinCyclophosphamideFluorouracilMitomycinNab-paclitaxelNiraparibOlaparibPembrolizumabChemo-substanceBevacizumabBinimetinibCisplatinCyclophosphamideFluorouracilMitomycinNab-paclitaxelNiraparibOlaparibPembrolizumabNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateNo. Substances235Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineTherapy phaseintraoperativMaintenanceTherapy intentionpalliativeRisksAlopeciaAnemia Hb below 8g/dlBleedingCardiotoxicityConstipationDiarrheaDyspneaEdemaElectrolyte DisturbanceEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFistulasGastrointestinal ToxicityHeadacheHypertensionHypomagnesemiaIncrease Creatinine PhosphokinaseInfectionsLymphopeniaNeutropeniaPainProteinuriaRashThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorGhanipour LGrisham RNKuijpers AMirza MMoore K / Pujade-Lauraine ETillmanns Tvan Driel WZsiros RDiseaseNeudiagnostiziertes Ovarial-Ca, Eileiter-Ca oder Peritoneal-Ca, Stadium III mit neoadjuvanter Therapie, ECOG 0-2Ovarial-Ca, Rezidiv, platinsensitiv, Zweitlinie, BRCA Mutation, ECOG 0-1Ovarialkarzinom, serös, low-grade oder Borderline-Tumor, Progress nach platinhaltiger ChemotherapiePeritonealkarzinom durch kolorektales Ca oder Pseudomyxoma peritonii, operabel, T1-T4, Stadium I-IVPeritonealkarzinose, sekundärrezidivierendes Ovarialkarzinom, fallopian tube or primary peritoneal cancer, ECOG 0-1rezidiviertes Ovarialkarzinom, Eileiterkarzinom oder primäres Peritonealkarzinom, Cisplatin-sensitiv, Drittlinie, ECOG 0-1wiederkehrendes oder fortschreitendes Ovarial-Ca/Peritoneal-Ca, Stadium I-IV, nach Platintherapie, ECOG 0-1OriginDepartment of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New YorkDepartment of Gynecology, Netherlands Cancer Institute, AmsterdamDepartment of Oncology, Rigshospitalet–Copenhagen University Hospital, ENGOT-OV16/NOVA InvestigatorsDepartment of Surgical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, AmsterdamMemorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, 3 MILO/ENGOT-ov11 StudyStevenson Cancer Center, University of Oklahoma, SOLO2/ENGOT-Ov21 investigatorsThe West Clinic, Memphis, USAUppsala University, Uppsala, SwedenProtocols in Revision 8 protocols foundProtocols under revision.Binimetinib 45, Ovarian Ca (PID2671 V1.0)EPIC - Fluorouracil 400, Peritoneal Carcinomatosis, Secondary (PID2709 V1.0)HIPEC - Cisplatin 100, Ovarian ca (PID108 V2.1)HIPEC - Mitomycin 35, Peritoneal Carcinomatosis, Secondary (PID123 V2.0)Nab-Paclitaxel 100 / Bevacizumab 10, Ovarian ca (PID900 V1.0)Niraparib 300, ovarian carcinoma, maintenance (PID477 V1.1)Olaparib 300, Ovarian ca, maintenance (PID531 V2.0)Pembrolizumab 200 / Bevacizumab 15 / Cyclophosphamide 50, Ovarian ca (PID1109 V1.1)
